Skyhawk Therapeutics
Dr. Ben Ebert focuses on the genetics, biology, and therapy of myeloid malignancies. His work has led to the characterization of clonal hematopoiesis as a pre-malignant state for hematologic malignancies, and elucidation of the mechanism of action of lenalidomide and related molecules that induce degradation of specific proteins. Dr. Ebert has served as president of the American Society for Clinical Investigation and is an elected member of the National Academy of Medicine and the Association of American Physicians. Dr. Ebert has a Ph.D. from Oxford University (Rhodes Scholar), a M.D. from Harvard Medical School, and did his residency in internal medicine at Massachusetts General Hospital and a fellowship in hematology/oncology at the Dana-Farber Cancer Institute.
This person is not in the org chart
This person is not in any offices
Skyhawk Therapeutics
1 followers
At Skyhawk Therapeutics we invent small molecules using proprietary kinetic, structural and computational models that correct RNA splicing and mis-spicing. Our small molecule platform accelerates drug development across a broad range of disease types.